Delivery Order SPE2DB22D3016-SPE2DB25FBCN7
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $22,727.25 to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (28-count package), with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is being performed from the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of IMBRUVICA 420 MG TABLET 28S. The fixed-price contract has a ceiling value of $37,878.75 and a performance period through July 23, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global...
- This is a $33,865.10 delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The order is for 4,568,188,793 units of the drug Imbruvica 420 mg tablets. The contract is a firm fixed-price delivery order with a period of performance through May 30, 2025. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products...
- This is a $14,645.34 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Imbruvica 420 mg tablets. The order has an ultimate completion date of September 17, 2024. AmerisourceBergen holds several indefinite delivery contracts (IDCs) with the DLA and other federal agencies for the provision of a wide range of pharmaceutical products and medical supplies to support military treatment...
- This federal contract award, valued at $15,151.52, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of IMBRUVICA 280 MG TABLET 28S, a pharmaceutical product, and has an ultimate completion date of April 14, 2025. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued...
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of IMBRUVICA 420 MG TABLET 28S. The contract has a ceiling value of $15,151.52 and a completion date of July 29, 2025. The contract is a Firm Fixed Price delivery order and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a for-profit pharmaceutical distribution company, to provide IMBRUVICA 420 mg tablets. The $43,936.02 order falls under an indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen holds with DLA to deliver a wide range of pharmaceuticals and medical supplies to support military treatment facilities worldwide. This order does not have a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (quantity 28) under a firm fixed-price contract. The order, valued at $7,575.75, was competitively awarded without a set-aside designation and is scheduled for completion by August 8, 2025. Performance will be executed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's existing...
- This federal contract award from the Defense Logistics Agency (DLA) is for the delivery of IMBRUVICA 420 mg tablets to support military and government healthcare programs. The $7,575.75 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of December 13, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $15,151.52 firm fixed-price contract is for the delivery of IMBRUVICA 420 MG TABLET 28S, a prescription medication. The delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBCN7Delivery Order
This delivery order, valued at $15,151.52, awards AmerisourceBergen Drug Corp the supply of IMBRUVICA 420 mg tablets (28-count units) under a competitive, non-set-aside procurement by the Defense Logistics Agency (DLA). The contract carries a firm fixed price structure with an ultimate completion date of August 11, 2025, and fulfillment will occur at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal healthcare vendor, supplies a comprehensive portfolio of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The company holds significant capacity within the federal medical supply chain, consistently delivering competitively awarded orders ranging from nominal to substantial values. IMBRUVICA, a specialty pharmaceutical for hematologic malignancies, represents part of the company's extensive offerings of brand-name and generic medications, specialty treatments, and medical supplies distributed through the DLA's global pharmaceutical support vehicle serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.2k | 7/21/25 |